Identifification of a novel LDLR-RET Fusion in Lung Adenocarcinoma
ConclusionsThis novel form of RET fusion in NSCLC is reported for the first time worldwide, offering a new treatment option for the patient with the possibility of using RET-selective inhibitors.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | China Health | Drugs & Pharmacology | Fish | Genetics | Investigational New Drugs | Lung Cancer | Non-Small Cell Lung Cancer | Study